Genomic BCR-ABL1 breakpoint characterization by a multi-strategy approach for “personalized monitoring” of residual disease in chronic myeloid leukemia patients

For monitoring minimal residual disease (MRD) in chronic myeloid leukemia (CML) the most recommended method is quantitative RT-PCR (RT-qPCR) for measuring BCR-ABL1 transcripts. Several studies reported that a DNA-based assay enhances the sensitivity of detection of the BCR-ABL1 genomic rearrangement...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Cumbo, Cosimo, Impera, Luciana, Minervini, Crescenzio Francesco, Orsini, Paola, Anelli, Luisa, Zagaria, Antonella, Coccaro, Nicoletta, Tota, Giuseppina, Minervini, Angela, Casieri, Paola, Brunetti, Claudia, Rossi, Antonella Russo, Parciante, Elisa, Specchia, Giorgina, Albano, Francesco
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2018
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5834283/
https://ncbi.nlm.nih.gov/pubmed/29541390
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.23971
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires